The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study

MS Sandoz; GW Keusch

doi:10.4414/smw.2004.10492

Original article

Vol. 134 No. 3132 (2004)

The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study

MS Sandoz
GW Keusch

Fulltext PDF

Cite this as:: Swiss Med Wkly. 2004;134:440-447
Published: 07.08.2004

How to Cite

1.

The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study. Swiss Med Wkly [Internet]. 2004 Aug. 7 [cited 2025 Nov. 4];134(3132):440-7. Available from: https://smw.ch/index.php/smw/article/view/399

Share

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

DOI:: https://doi.org/10.4414/smw.2004.10492